Huang C.-L.YEN-WEN WUSHOEI-SHEN WANGTseng C.-D.FU-TIEN CHIANGHsu K.-L.CHII-MING LEEKAI-YUAN TZEN2020-03-052020-03-0520110914-7187https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052310465&doi=10.1007%2fs12149-011-0487-x&partnerID=40&md5=8e9d67d519e53b559028bb1122b0879fhttps://scholars.lib.ntu.edu.tw/handle/123456789/470997Objective: Recent investigation has demonstrated that prostaglandin E 1 (PGE 1) therapy increased capillary density in explanted hearts. Dynamic 13N-ammonia positron emission tomography (PET) is reliable for non-invasive measurement of myocardial blood flow and myocardial perfusion reserve (MPR). The aim of this study was to investigate the effects of PGE 1 therapy during 4 weeks on reduction of myocardial perfusion abnormalities and increase of MPR in the patients with ischemic heart disease. Methods: In this double-blind, placebo-controlled trial, we randomly assigned 11 patients who had symptomatic heart failure and documented myocardial ischemia to 4 weeks intravenous infusion of PGE 1 (2.5 ng/kg/min; 8 patients, age 60 ± 13 years) or saline (3 patients, age 57 ± 13 years). Dynamic 13N-ammonia PET scans at rest and during adenosine stress were obtained at baseline and 12 weeks after treatment completion. Quantitative size/severity of perfusion defects and MPR change from baseline to follow-up PET were determined using a 17-segment model. Results: Compared with the control group, baseline MPR in the PGE 1 group was significantly lower (1.96 ± 0.78 vs. 2.71 ± 0.73; P < 0.001). MPR significantly improved 12 weeks after completion of PGE 1 infusion (1.96 ± 0.78 to 2.16 ± 0.77; P < 0.001). In contrast, MPR declined significantly in the placebo group (2.71 ± 0.73 to 2.01 ± 0.58, P < 0.001). Conclusion: Four weeks of PGE 1 infusion sustained MPR improvement in patients with ischemic heart disease. This may be an attractive therapeutic approach for no-option patients with severe ischemic cardiomyopathy. ? 2011 The Japanese Society of Nuclear Medicine.[SDGs]SDG3ammonia n 13; dipyridamole tl 201; placebo; prostaglandin E1; radiopharmaceutical agent; unclassified drug; adult; aged; article; clinical article; continuous infusion; controlled study; disease severity; double blind procedure; female; follow up; heart failure; heart muscle ischemia; heart muscle perfusion; human; ischemic heart disease; low drug dose; male; pilot study; positron emission tomography; priority journal; quantitative analysis; randomized controlled trial; single photon emission computer tomography; treatment duration; Adult; Aged; Aged, 80 and over; Alprostadil; Ammonia; Cicatrix; Coronary Circulation; Female; Heart; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Pilot Projects; Positron-Emission Tomography; Prospective Studiesjournal article10.1007/s12149-011-0487-x214615962-s2.0-80052310465